Xaira Therapeutics is an integrated biotechnology company founded in 2023 that combines AI model development, large-scale biological data generation, and therapeutic product development under one organization. Built on protein design research from the University of Washington's Institute for Protein Design and Dr. David Baker's work, the company raised over $1 billion before emerging from stealth in 2024. Co-founded and incubated by ARCH Venture Partners and Foresite Labs, Xaira operates across three locations: South San Francisco, Seattle, and London.
The technical infrastructure spans protein design, predictive patient stratification, and drug discovery systems. The stack includes Python, C++, PyTorch, and Jax for modeling, with distributed training approaches using DDP and FSDP. Experimental infrastructure includes Cytiva AKTA and Agilent HPLC systems for protein characterization and purification workflows. The company's approach integrates computational predictions with wet-lab data generation at scale, attempting to shift drug discovery from empirical methods toward engineered precision.
Technical domains span AI model development for biological systems, protein engineering, therapeutic design, and patient selection algorithms. The organization is led by David Baker and Marc Tessier-Lavigne, combining academic protein design expertise with pharmaceutical development experience. The integration of model training, experimental validation loops, and therapeutic development pipeline represents a vertically integrated structure where data generation, model iteration, and product development occur within the same organization.